Maven Securities LTD Invests $366,000 in Surmodics, Inc. $SRDX

Key Points

• Maven Securities LTD has acquired a stake in Surmodics, Inc. worth approximately $366,000, holding 12,000 shares which amounts to 0.08% of the company.
• Several other hedge funds also invested in Surmodics during the last quarter, contributing to institutional investors holding 96.63% of the company's stock.
• Surmodics reported an earnings per share of $0.06 for the latest quarter, exceeding expectations, and set a guidance for FY 2025 of -0.350--0.200 EPS.

Maven Securities LTD purchased a new stake in Surmodics, Inc. (NASDAQ:SRDX - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 12,000 shares of the company's stock, valued at approximately $366,000. Maven Securities LTD owned approximately 0.08% of Surmodics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Wellington Management Group LLP acquired a new position in Surmodics in the first quarter valued at approximately $815,000. Algert Global LLC boosted its holdings in Surmodics by 146.3% in the first quarter. Algert Global LLC now owns 35,122 shares of the company's stock valued at $1,072,000 after purchasing an additional 20,862 shares in the last quarter. Nuveen LLC acquired a new position in Surmodics in the first quarter valued at approximately $1,262,000. Invesco Ltd. boosted its holdings in Surmodics by 103.9% in the first quarter. Invesco Ltd. now owns 11,844 shares of the company's stock valued at $362,000 after purchasing an additional 6,036 shares in the last quarter. Finally, Burren Capital Advisors Ltd acquired a new position in Surmodics in the first quarter valued at approximately $1,094,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Surmodics Stock Performance

Shares of Surmodics stock traded down $0.4550 during trading hours on Monday, hitting $36.7350. 25,158 shares of the company were exchanged, compared to its average volume of 193,322. Surmodics, Inc. has a 1 year low of $26.00 and a 1 year high of $40.38. The company has a current ratio of 3.91, a quick ratio of 3.10 and a debt-to-equity ratio of 0.27. The business has a 50-day moving average of $32.86 and a 200-day moving average of $30.92. The stock has a market capitalization of $525.31 million, a price-to-earnings ratio of -29.95 and a beta of 1.31.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.27. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%.The business had revenue of $29.57 million during the quarter, compared to analysts' expectations of $28.04 million. Surmodics has set its FY 2025 guidance at -0.350--0.200 EPS. As a group, analysts expect that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SRDX has been the subject of a number of research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th. Zacks Research raised Surmodics to a "hold" rating in a report on Tuesday, August 12th. Finally, Barrington Research reissued a "market perform" rating on shares of Surmodics in a report on Monday, August 11th. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $43.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).